Table 1

Patients characteristics, costs and outcomes

CharacteristicsPPOIT (n=28)Placebo (n=28)DifferenceP value
At trial entry
 Age in years, mean (SD)6.0 (2.6)5.8 (2.8)0.30.70
 Females, % (n)36% (10)32% (9)4%0.78
 History of doctor-diagnosed asthma (ever), % (n)57% (16)50% (14)7%0.59
Costs, A$ ($A1=£0.5 approximately)
 Costs, 1.5 years of treatment
  Treatment cost497204972
  Doctor244202442
  Nurse110101101
  PPOIT112401124
  Pathology tests and epinephrine autoinjector3050305
  Adverse events, mean (SD)905 (656)719 (528)1860.25
 Cost, 4 years of post-treatment follow-up
  Adverse events, mean (SD)1739 (672)169 (141)1570<0.001
  Peanut allergy events4 (21)35 (128)−310.20
  Asthma events*1735 (674)133 (29)1602<0.001
 Cost, post follow-up over 4.5 years (extrapolation)†
  Adverse events, mean (SD)1739 (672)169 (141)1570
Outcomes, mean (SD)
 SU rate, end of 1.5 years of treatment0.82 (0.39)0.04 (0.19)0.79<0.001
 SU rate, 4-year post-treatment follow-up0.58 (0.51)0.07 (0.26)0.520.002
 SU rate, end of 10 years (extrapolation)‡0.32 (0.51)0.10 (0.26)0.21
 AQoL-6D, baseline0.86 (0.09)0.82 (0.11)0.040.19
 AQoL-6D, end of 1.5 years of treatment0.83 (0.10)0.89 (0.10)−0.070.022
 AQoL-6D, 0.25-year post-treatment follow-up0.86 (0.12)0.87 (0.11)−0.020.66
 AQoL-6D, 1-year post treatment follow-up0.85 (0.09)0.84 (0.14)0.020.65
 AQoL-6D, 4-year post-treatment follow-up0.95 (0.04)0.86 (0.13)0.100.004
 AQoL-6D, end of 10 years (extrapolation)‡0.92 (0.04)0.89 (0.13)0.03
  • Student’s t-test for continuous outcomes and χ2 tests for dichotomous outcomes were used.

  • *Last available follow-up survey was used whereas the recall period was 6 months. The estimated cost for 6 months was multiplied by 8 to approximate the cost over the 4 years post treatment.

  • †Assumed to follow the same pattern as seen for the 4 years post treatment.

  • ‡Mean values were estimated using assumed trends while SD were assumed to be the same as the previous observable point.

  • AQoL-6D, Assessment of Quality-of-life-6D.